TY - JOUR
T1 - In vitro and in vivo activity of Aloe vera leaf exudate in experimental visceral leishmaniasis
AU - Dutta, Avijit
AU - Sarkar, Debjani
AU - Gurib-Fakim, Ameenah
AU - Mandal, Chitra
AU - Chatterjee, Mitali
PY - 2008/5
Y1 - 2008/5
N2 - The leishmanicidal activity of Aloe vera leaf exudate (AVL) has been demonstrated in promastigotes and axenic amastigotes, but its effectiveness in animal models has not been evaluated. The presence of alkaloids, triterpenes, cyanidines, proanthocyanidines, tannins, and saponins in AVL was identified. Its effectiveness in four Leishmania donovani strains was studied both in promastigotes (IC50 ranged from 70-115 μg/ml) and amastigotes (IC50 ranged from 3.1-11.4 μg/ml). In amastigotes, the killing by AVL was facilitated through its induction of nitric oxide in leishmania-infected macrophages. The safety index was good as AVL up to 300 μg/ml remained non-toxic to monocytes and macrophages. In a L. donovani BALB/c mouse model, oral or subcutaneous administration of AVL (15 mg/kg body weight×5 days) reduced parasitemia by >90% in the liver, spleen, and bone marrow without impairment of hepatic and renal functions. Collectively, we conclude that AVL shows promising antileishmanial activity and may provide a new lead agent in the treatment of Leishmaniasis.
AB - The leishmanicidal activity of Aloe vera leaf exudate (AVL) has been demonstrated in promastigotes and axenic amastigotes, but its effectiveness in animal models has not been evaluated. The presence of alkaloids, triterpenes, cyanidines, proanthocyanidines, tannins, and saponins in AVL was identified. Its effectiveness in four Leishmania donovani strains was studied both in promastigotes (IC50 ranged from 70-115 μg/ml) and amastigotes (IC50 ranged from 3.1-11.4 μg/ml). In amastigotes, the killing by AVL was facilitated through its induction of nitric oxide in leishmania-infected macrophages. The safety index was good as AVL up to 300 μg/ml remained non-toxic to monocytes and macrophages. In a L. donovani BALB/c mouse model, oral or subcutaneous administration of AVL (15 mg/kg body weight×5 days) reduced parasitemia by >90% in the liver, spleen, and bone marrow without impairment of hepatic and renal functions. Collectively, we conclude that AVL shows promising antileishmanial activity and may provide a new lead agent in the treatment of Leishmaniasis.
UR - http://www.scopus.com/inward/record.url?scp=42049086101&partnerID=8YFLogxK
U2 - 10.1007/s00436-008-0899-2
DO - 10.1007/s00436-008-0899-2
M3 - 文章
C2 - 18266009
AN - SCOPUS:42049086101
SN - 0932-0113
VL - 102
SP - 1235
EP - 1242
JO - Parasitology Research
JF - Parasitology Research
IS - 6
ER -